Focal Onset Seizures Clinical Trials

13 clinical trials for Focal Onset Seizures across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures — RECRUITING · PHASE2
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) — RECRUITING · PHASE3
• SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures — RECRUITING · PHASE2
• RENAISSANCE 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures — TERMINATED · PHASE2
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures — COMPLETED · PHASE3
• Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy — COMPLETED · PHASE2
• A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy — COMPLETED · PHASE2
• Study of EQU-001 for Uncontrolled Focal Onset Seizures — TERMINATED · PHASE2
• Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy — COMPLETED · PHASE2
• A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy — TERMINATED · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF XEN1101 AS ADJUNCTIVE THERAPY IN FOCAL-ONSET SEIZURES — COMPLETED · PHASE3
• Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy — TERMINATED · PHASE2
• AN OPEN LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY — COMPLETED

Refine this search